As of November 9, 2026, SAB Biotherapeutics, Inc. is a publicly traded company (Nasdaq: SABS). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 9.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Vivo Opportunity Fund Holdings, L.P. (9.99%), Commodore Capital (9.9%), Balyasny Asset Management L.P. (9.45%) (Schedule 13D/A, August 10, 2026).
Is this your company?
About to sign with, pay or invest in SAB Biotherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is SAB Biotherapeutics, Inc. a real, registered company?
- SAB Biotherapeutics, Inc. files with the SEC under CIK 1833214 (its SEC filings).
- Its shares are listed under the ticker SABS on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Miami Beach, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SAB Biotherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-09).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Caligan Partners LP (filed 2026-08-14).
Who are SAB Biotherapeutics, Inc.'s owners and officers?
SAB Biotherapeutics, Inc.: incorporated in Delaware; business address in Miami Beach, Florida; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-08-05)
- : Executive Officer, Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
- : Director (Form D, 2025-08-05)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Caligan Partners LP | 8.8% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 9.45% |
| Schedule 13G/A, 2026-08-14 | Woodline Partners LP | 6.8% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 7.3% |
| Schedule 13G/A, 2026-08-14 | Vivo Opportunity Fund Holdings, L.P. | 9.99% |
| Schedule 13G/A, 2026-08-14 | Commodore Capital LP | 9.9% |
| Schedule 13G, 2026-08-12 | Adage Capital Management, L.P. | 8.38% |
| Schedule 13D/A, 2026-08-10 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G, 2026-05-15 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-05-15 | Caligan Partners LP | 10.4% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 8.4% |
| Schedule 13G, 2026-05-01 | Millennium Management LLC | 5.1% |
Questions about who owns SAB Biotherapeutics, Inc.
Who owns SAB Biotherapeutics, Inc.?
On this page, 9 holders' latest ownership filings report 5% or more of SAB Biotherapeutics, Inc.: Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-08-14), Ra Capital Management, L.P. (9.9%, Schedule 13D/A, filed 2026-08-10), Balyasny Asset Management L.P. (9.45%, Schedule 13G/A, filed 2026-08-14) and Caligan Partners LP (8.8%, Schedule 13G/A, filed 2026-08-14); 4 more are listed above.
Who are the largest shareholders of SAB Biotherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of SAB Biotherapeutics, Inc. on this page are Vivo Opportunity Fund Holdings, L.P. (9.99%), Commodore Capital LP (9.9%) and Ra Capital Management, L.P. (9.9%).
When did Vivo Opportunity Fund Holdings, L.P. buy into SAB Biotherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Vivo Opportunity Fund Holdings, L.P. on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on SAB Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on SAB Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SAB Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own SAB Biotherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Sessa Capital (Master), L.P., a director: 2,198,457 shares (2.4% of shares outstanding), on a joint filing (Form 4, 2025-10-01).
- , a director: 2,198,457 shares (2.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2025-10-01).
- Sessa Capital GP, LLC, a director: 2,198,457 shares (2.4% of shares outstanding), on a joint filing (Form 4, 2025-10-01).
- , a director: 2,198,457 shares (2.4% of shares outstanding), on a joint filing (Form 4, 2025-10-01).
- Sessa Capital IM, L.P., a director: 2,198,457 shares (2.4% of shares outstanding), on a joint filing (Form 4, 2025-10-01).
Shares outstanding: 90,088,831 as of 2026-11-02, from the company's latest SEC cover page.
How much has SAB Biotherapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-08-05 | $175M | $175M |
| Form D, 2023-10-16 | $7.50M | $7.50M |
Keep reading
More on SAB Biotherapeutics, Inc. and the records around it.
SAB Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Aug 2025
Companies that share a holder
- Caligan Partners LP also filed stake reports on 9 other companies: Avalo Therapeutics, Inc. (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sab-biotherapeutics